216 related articles for article (PubMed ID: 8262557)
1. Differential effects of small tumour necrosis factor-alpha peptides on tumour cell cytotoxicity, neutrophil activation and endothelial cell procoagulant activity.
Rathjen DA; Ferrante A; Aston R
Immunology; 1993 Oct; 80(2):293-9. PubMed ID: 8262557
[TBL] [Abstract][Full Text] [Related]
2. Effects of hyperthermia and tumour necrosis factor on inflammatory cytokine secretion and procoagulant activity in endothelial cells.
Gnant MF; Turner EM; Alexander HR
Cytokine; 2000 Apr; 12(4):339-47. PubMed ID: 10805214
[TBL] [Abstract][Full Text] [Related]
3. A synthetic tumor necrosis factor-alpha agonist peptide enhances human polymorphonuclear leukocyte-mediated killing of Plasmodium falciparum in vitro and suppresses Plasmodium chabaudi infection in mice.
Kumaratilake LM; Rathjen DA; Mack P; Widmer F; Prasertsiriroj V; Ferrante A
J Clin Invest; 1995 May; 95(5):2315-23. PubMed ID: 7738194
[TBL] [Abstract][Full Text] [Related]
4. TNF 41-62 and TNF 78-96 have distinct effects on LPS-induced tissue factor activity and the production of cytokines in human blood cells.
Eliassen LT; Rekdal O; Svendsen JS; Osterud B
Thromb Haemost; 2000 Apr; 83(4):598-604. PubMed ID: 10780324
[TBL] [Abstract][Full Text] [Related]
5. Differences in the biological activity of TNF alpha and TNF beta correlate with their different abilities for binding to the target cells.
Kircheis R; Milleck J; Korobko VG; Shingarova LN; Schmidt HE
Eur Cytokine Netw; 1992; 3(4):381-90. PubMed ID: 1330049
[TBL] [Abstract][Full Text] [Related]
6. Biological activity of mutants of human tumour necrosis factor-alpha.
Kircheis R; Milleck J; Korobko VG; Shingarova LN; Behnke D; Schmidt HE
Immunology; 1992 Jul; 76(3):433-8. PubMed ID: 1526652
[TBL] [Abstract][Full Text] [Related]
7. Improvement of potential therapeutic value of tumor necrosis-alpha (TNF-alpha) by charge modulation in the tip region.
Fonda I; Pernus M; Gaberc-Porekar V; Kenig M; Stalc A; Meager A; Menart V
Eur Cytokine Netw; 2005; 16(1):17-26. PubMed ID: 15809202
[TBL] [Abstract][Full Text] [Related]
8. Changes in coagulation and permeability properties of human endothelial cells in vitro induced by TNF-alpha or 5,6 MeXAA.
Watts ME; Arnold S; Chaplin DJ
Br J Cancer Suppl; 1996 Jul; 27():S164-7. PubMed ID: 8763872
[TBL] [Abstract][Full Text] [Related]
9. Human TNF mutants with selective activity on the p55 receptor.
Van Ostade X; Vandenabeele P; Everaerdt B; Loetscher H; Gentz R; Brockhaus M; Lesslauer W; Tavernier J; Brouckaert P; Fiers W
Nature; 1993 Jan; 361(6409):266-9. PubMed ID: 8380906
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of tumor necrosis factor-alpha for human umbilical vein endothelial cells.
Schuger L; Varani J; Marks RM; Kunkel SL; Johnson KJ; Ward PA
Lab Invest; 1989 Jul; 61(1):62-8. PubMed ID: 2747218
[TBL] [Abstract][Full Text] [Related]
11. Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte- activating polypeptide II (EMAP-II).
Berger AC; Alexander HR; Wu PC; Tang G; Gnant MF; Mixon A; Turner ES; Libutti SK
Cytokine; 2000 Jul; 12(7):992-1000. PubMed ID: 10880244
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil-activating activity and platelet-activating factor synthesis in cytokine-stimulated endothelial cells: reduced activity in growth-arrested cells.
Takahashi T; Nishizawa Y; Hato F; Shintaku H; Maeda N; Fujiwara N; Inaba M; Kobayashi K; Kitagawa S
Microvasc Res; 2007 Jan; 73(1):29-34. PubMed ID: 17027041
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil alpha-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells.
Chaly YV; Paleolog EM; Kolesnikova TS; Tikhonov II; Petratchenko EV; Voitenok NN
Eur Cytokine Netw; 2000 Jun; 11(2):257-66. PubMed ID: 10903805
[TBL] [Abstract][Full Text] [Related]
14. Effect of endogenous nitric oxide on tumour necrosis factor-alpha-induced leukosequestration and IL-8 release in guinea-pigs airways in vivo.
Kuo HP; Hwang KH; Lin HC; Wang CH; Lu LC
Br J Pharmacol; 1997 Sep; 122(1):103-11. PubMed ID: 9298535
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of tumor necrosis factor alpha conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice.
Kaneda Y; Yamamoto Y; Kamada H; Tsunoda S; Tsutsumi Y; Hirano T; Mayumi T
Cancer Res; 1998 Jan; 58(2):290-5. PubMed ID: 9443407
[TBL] [Abstract][Full Text] [Related]
16. [Definition of tumor-necrosis factor and its production mechanism].
Urushizaki I; Niitsu Y; Watanabe N
Gan To Kagaku Ryoho; 1984 Jul; 11(7):1356-68. PubMed ID: 6378100
[TBL] [Abstract][Full Text] [Related]
17. The intravenous administration of tumor necrosis factor alpha, interleukin 8 and macrophage-derived neutrophil chemotactic factor inhibits neutrophil migration by stimulating nitric oxide production.
Tavares-Murta BM; Cunha FQ; Ferreira SH
Br J Pharmacol; 1998 Aug; 124(7):1369-74. PubMed ID: 9723947
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK
Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523
[TBL] [Abstract][Full Text] [Related]
19. Effects of antirheumatic gold salts on cytokine-induced neutrophil-dependent cytotoxicity for human endothelial cells.
Bratt J; Palmblad J
J Investig Med; 2000 Nov; 48(6):395-402. PubMed ID: 11094861
[TBL] [Abstract][Full Text] [Related]
20. A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides.
Qin W; Feng J; Li Y; Lin Z; Shen B
Mol Immunol; 2007 Mar; 44(9):2355-61. PubMed ID: 17125837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
